Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Amyl Therapeutics raises €8.25M in Series A extension funding to support the development of its clinical candidate. The round was backed by Noshaq and Merieux Equity Partners.

PRIVATESep 01, 2026•7 days ago

Amount Raised

€8.25 Million

Round Type

Series A

LiègeBiotechnologyTherapeutics

Investors

Merieux Equity PartnersNoshaq

Description

Amyl Therapeutics, a Liege, Belgium-based preclinical stage biotechnology company, raised €8.25M in an extension of its Series A financing. The funds will be used to finalize development of its clinical candidate for GMP manufacturing and complete necessary preclinical testing. This extension brings their total Series A to €27.85M. The company is focused on developing therapies for diseases linked to amyloid fibrils.

Company Information

Company

Amyl Therapeutics

Location

Liège, Belgium

About

Amyl Therapeutics is a preclinical stage biotechnology company based in Liege, Belgium. The company develops a technology platform designed to treat diseases linked to amyloid fibrils, particularly neurodegenerative diseases. They utilize a fusion protein engineered to recognize and neutralize toxic protein aggregates and incorporate technology to enhance blood-brain barrier passage. The firm is focused on finalizing development of its clinical candidate and validating its platform.

Don't miss Amyl Therapeutics's next move

Get an email the moment Amyl Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Amyl Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Amyl Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.